About Careers MedBlog Contact us

Pfizer to Fight Against Canadian Firm's Anti-cholesterol Drug

by VR Sreeraman on January 4, 2008 at 5:28 PM
Font : A-A+

Pfizer to Fight Against Canadian Firm's Anti-cholesterol Drug

US drug giant Pfizer said Thursday it will appeal a Canadian federal court decision paving the way for the pharmaceutical firm Apotex to launch a generic version of its anti-cholesterol drug Lipitor.

The court had previously denied Pfizer's request to prevent Apotex from launching a generic version of Lipitor prior to the expiration of a Pfizer patent in July 2010.


The drug (atorvastatin calcium) has generated 13 billion dollars in sales worldwide for Pfizer, making it the leading cholesterol-lowering medication.

Lipitor is used to treat high cholesterol, helping to prevent heart disease and hardening of the arteries -- conditions that can lead to heart attack, stroke, and vascular disease.

Pfizer said the Canadian court's decision "has no immediate commercial impact because Lipitor is protected by other patents in Canada, which also are the subject of pending legal challenges."

The ruling by the federal court also has no impact on Lipitor patent litigation in other countries, the company said.

Source: AFP


Recommended Reading

Latest Drug News

 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
Sacubitril/valsartan Unleashes Hope for Heart Failure Patients
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Pfizer to Fight Against Canadian Firm's Anti-cholesterol Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests